Latest news
PRESSRELEASE New patent for ICOone
PRESSRELEASE 230126:
The European Patent Office EPO intends to approve Iconovo's patent application for the inhaler platform ICOone® (Communication…
Iconovo i Penserpodden
Penserpodden är en podd om aktier, börs och marknad där några av våra mest framstående förvaltare och analytiker går igenom allt från både…
Press releases
Apr 28, 2021, 08:35
News
IR
Swedish
Regulatory
Listing Regulation
Report
Annual
Apr 27, 2021, 09:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Apr 27, 2021, 09:30
News
IR
English
Corporate Information
Other Corporate Information
Apr 21, 2021, 13:15
News
IR
English
Corporate Information
Other Corporate Information
Apr 21, 2021, 13:15
News
IR
Swedish
Corporate Information
Other Corporate Information
Apr 19, 2021, 14:35
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Mar 31, 2021, 14:05
News
IR
English
Regulatory
MAR
Corporate Information
Sales
Order
Mar 31, 2021, 14:05
News
IR
Swedish
Regulatory
MAR
Corporate Information
Sales
Order
Mar 15, 2021, 09:55
News
PR
Swedish
Mar 11, 2021, 12:05
News
IR
Swedish
Corporate Information
Other Corporate Information
Mar 11, 2021, 12:05
News
IR
English
Corporate Information
Other Corporate Information
Feb 18, 2021, 12:50
News
IR
English
Corporate Information
Other Corporate Information
Feb 17, 2021, 13:00
News
IR
Swedish
Corporate Information
Other Corporate Information
Feb 17, 2021, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 10, 2021, 08:30
News
IR
English
Corporate Information
Other Corporate Information
Feb 10, 2021, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Feb 04, 2021, 08:30
News
IR
English
Corporate Information
Other Corporate Information
Feb 04, 2021, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Feb 03, 2021, 08:14
News
IR
Swedish
Regulatory
MAR
Corporate Information
Sales
Order
Feb 02, 2021, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se